---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-23-017420"
form_type: "8-K"
ticker: "PRME"
cik: "0001894562"
company_name: "Prime Medicine, Inc."
filed_at: "2023-05-11T23:59:59+00:00"
generated_at: "2026-06-15T04:59:11.230142+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.25
calibrated_materiality_score: 0.25
confidence: "high"
source: SEC EDGAR
---

# Prime Medicine appoints Jeff Marrazzo to board of directors

## Summary
- Jeff Marrazzo appointed as Class II director effective May 10, 2023, until 2024 annual meeting.
- Granted stock options for 92,000 shares vesting in three equal annual installments.
- Annual cash compensation of $40,000 for board service and $6,000 for Compensation Committee.
- Also appointed to the Compensation Committee.
- No arrangements or transactions requiring disclosure under Item 404(a).

## SEC filing metadata
- accession: 0001628280-23-017420
- form_type: 8-K
- ticker: PRME
- cik: 0001894562
- company_name: Prime Medicine, Inc.
- filed_at: 2023-05-11T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.25
- calibrated_materiality_score: 0.25
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1894562/000162828023017420/0001628280-23-017420-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1894562/000162828023017420/prme-20230510.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-23-017420
- JSON: https://secwatch.observer/filing/0001628280-23-017420.json
- Plain text: https://secwatch.observer/filing/0001628280-23-017420.txt

## Key facts
- Executive change
  Jeff Marrazzo was appointed as Director at Prime Medicine, Inc..
  - Action: appointed
  - Role: Director
  source text: On May 10, 2023, the Board of Directors (the “Board”) of Prime Medicine, Inc. (the “Company”) appointed Jeff Marrazzo as a director of the Company.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1894562/000162828023017420/0001628280-23-017420-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.